IMUX FY 2020 Earnings — Immunic, Inc. Revenue & Financial Results | Market Cap Arena

IMUXImmunic, Inc.

$138M

FY 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$49M

Net Income

-$44M

EPS (Diluted)

$-2.81

Cash Flow

Operating Cash Flow

-$46M

Free Cash Flow

-$46M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$168M

Total Liabilities

$9M

Stockholders' Equity

$159M

Cash & Equivalents

$127M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	-$50,000	+100.0%
Operating Income	-$49M	-$37M	-32.2%
Net Income	-$44M	-$35M	-26.4%